Merus Labs International (Merus Labs International) EBIT per Share : $-0.03 (TTM As of Mar. 2017)

View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International EBIT per Share?

Merus Labs International's EBIT per Share for the three months ended in Mar. 2017 was $0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2017 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Merus Labs International's EBIT per Share or its related term are showing as below:

MSLI's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 8.05
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Merus Labs International's EBIT for the three months ended in Mar. 2017 was $0.84 Mil.

Merus Labs International EBIT per Share Historical Data

The historical data trend for Merus Labs International's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International EBIT per Share Chart

Merus Labs International Annual Data

Trend

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

EBIT per Share

Get a 7-Day Free Trial

-0.94

0.13

-0.07

0.03

-0.01

Merus Labs International Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.01	0.01	-0.03	0.01

Merus Labs International EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Merus Labs International's EBIT per Share for the fiscal year that ended in Sep. 2016 is calculated as

	EBIT per Share		(A: Sep. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.388	/	110.937
=	-0.01

Merus Labs International's EBIT per Share for the quarter that ended in Mar. 2017 is calculated as

	EBIT per Share		(Q: Mar. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.84	/	117.205
=	0.01

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

Merus Labs International (NAS:MSLI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Merus Labs International EBIT per Share Related Terms

Thank you for viewing the detailed overview of Merus Labs International's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus Labs International (Merus Labs International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.meruslabs.com

Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines

From GuruFocus

Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals

By Gordon Pape Gordon Pape • 10-05-2015

Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc.

By Gordon Pape Gordon Pape • 06-22-2015

Merus Labs International: A Pharma Stock With Growth Potential

By Gordon Pape Gordon Pape • 03-30-2015